Advertisement
Advertisement
U.S. markets open in 3 hours 12 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Xeris Biopharma Holdings, Inc. (XERS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.5400-0.0200 (-1.28%)
At close: 04:00PM EDT
1.5200 -0.02 (-1.30%)
After hours: 06:03PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close1.5600
Open1.5500
Bid0.0000 x 1300
Ask0.0000 x 1100
Day's Range1.4900 - 1.5500
52 Week Range1.2500 - 3.1700
Volume618,592
Avg. Volume818,677
Market Cap209.374M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.4160
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XERS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Xeris Biopharma Holdings, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Rating
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • Zacks

    Xeris Biopharma (XERS) Upgraded to Buy: Here's What You Should Know

    Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • Business Wire

    Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events

    CHICAGO, August 10, 2022--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter and six months ended June 30, 2022 and upcoming events.

  • Business Wire

    Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022

    CHICAGO, August 03, 2022--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing differentiated and innovative products across a range of therapies, today announced that the Company will release its second quarter 2022 financial results before the open of the U.S. financial markets on Wednesday, August 10, 2022. Management will host a conference call and webcast at 8:30 a.m. Eastern Time th

Advertisement
Advertisement